Pay in 4 interest-free payments of $7.19 Learn more
Ships within 48 hours · Estimated delivery Aug 13 - Aug 18
DPP-4 Inhibitors Mechanism of action Competitive inhibition of dipeptidyl-peptidase 4 slows degradation of endogenous incretins (GLP-1, GIP) Glucose-dependent insulin secretion Post-prandial glucagon release No direct effect on weight or insulin sensitivity Glycaemic efficacy Advantages Weight-neutral useful when metformin + SU cause weight concern Low hypoglycaemia risk (incretin-dependent action) Oral, generally once-daily
Injectable GLP-1 medications are administered via a small subcutaneous injection, typically once weekly (semaglutide, tirzepatide) or once daily (liraglutide)
Oncogene 21 , 10481061 (2002)
In laboratory settings, it is commonly used as a diluent for the reconstitution of lyophilized research compounds when multiple withdrawals from the same vial are r
Your genetics, metabolism, and overall health can all influence how your body responds to the medication
Use this literacy to ask better clinical questions and to separate endogenous physiology from medication marketing
